IRIS
CIVES, MAURO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 3.848
AS - Asia 1.715
EU - Europa 1.058
SA - Sud America 528
AF - Africa 69
OC - Oceania 5
Continente sconosciuto - Info sul continente non disponibili 2
Totale 7.225
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 3.786
SG - Singapore 695
BR - Brasile 439
CN - Cina 404
HK - Hong Kong 250
SE - Svezia 220
IT - Italia 197
RU - Federazione Russa 190
VN - Vietnam 165
GB - Regno Unito 95
DE - Germania 90
FI - Finlandia 57
FR - Francia 45
ID - Indonesia 44
AR - Argentina 39
IN - India 34
CA - Canada 32
BD - Bangladesh 25
CI - Costa d'Avorio 25
AT - Austria 22
JP - Giappone 22
BE - Belgio 21
PL - Polonia 21
ZA - Sudafrica 21
NL - Olanda 20
IQ - Iraq 19
MX - Messico 19
UA - Ucraina 19
TR - Turchia 14
IE - Irlanda 13
LT - Lituania 12
ES - Italia 11
CO - Colombia 10
PY - Paraguay 10
EC - Ecuador 8
MA - Marocco 8
CL - Cile 6
PK - Pakistan 6
VE - Venezuela 6
MK - Macedonia 5
UZ - Uzbekistan 5
AZ - Azerbaigian 4
OM - Oman 4
RS - Serbia 4
SA - Arabia Saudita 4
UY - Uruguay 4
BO - Bolivia 3
CR - Costa Rica 3
ET - Etiopia 3
HN - Honduras 3
HU - Ungheria 3
KE - Kenya 3
KZ - Kazakistan 3
PE - Perù 3
TH - Thailandia 3
TN - Tunisia 3
AO - Angola 2
AU - Australia 2
CH - Svizzera 2
GR - Grecia 2
IL - Israele 2
JO - Giordania 2
LB - Libano 2
NZ - Nuova Zelanda 2
RO - Romania 2
TT - Trinidad e Tobago 2
XK - ???statistics.table.value.countryCode.XK??? 2
AE - Emirati Arabi Uniti 1
AL - Albania 1
AM - Armenia 1
BA - Bosnia-Erzegovina 1
BB - Barbados 1
BH - Bahrain 1
BY - Bielorussia 1
DM - Dominica 1
EE - Estonia 1
EG - Egitto 1
GA - Gabon 1
GT - Guatemala 1
HR - Croazia 1
IR - Iran 1
IS - Islanda 1
MT - Malta 1
NP - Nepal 1
PS - Palestinian Territory 1
QA - Qatar 1
SN - Senegal 1
SO - Somalia 1
TV - Tuvalu 1
TW - Taiwan 1
Totale 7.225
Salva come PNG Salva come JPEG
Città #
Fairfield 502
Ashburn 491
Woodbridge 389
Singapore 347
Hong Kong 247
Houston 230
Seattle 219
Chandler 210
Cambridge 203
Beijing 192
Nyköping 186
Wilmington 186
Ann Arbor 123
Los Angeles 75
Lawrence 64
Jacksonville 60
Dallas 59
Roxbury 58
Ho Chi Minh City 57
New York 46
Jakarta 39
Nanjing 39
Des Moines 36
Bari 35
Chicago 31
São Paulo 31
Buffalo 29
Inglewood 28
London 28
Munich 28
Helsinki 26
Santa Clara 25
Abidjan 24
Dong Ket 23
Redwood City 21
Tokyo 21
Brooklyn 19
Brussels 19
Paris 19
Rome 19
San Diego 19
Hanoi 18
Johannesburg 17
Nuremberg 17
Warsaw 17
Brasília 15
Princeton 15
Belo Horizonte 14
Moscow 14
Turku 14
Dublin 13
Chennai 12
Rio de Janeiro 12
Düsseldorf 11
Boardman 10
Mexico City 10
Montreal 10
Orem 10
Shenyang 10
Toronto 10
Vienna 10
Dearborn 9
Haiphong 9
Nanchang 9
Stockholm 9
Changsha 8
Curitiba 8
Pune 8
Ankara 7
Atlanta 7
Buenos Aires 7
Denver 7
Elk Grove Village 7
Frankfurt am Main 7
Guangzhou 7
Ninh Bình 7
San Jose 7
Vibo Valentia 7
Falkenstein 6
Hebei 6
Jiaxing 6
Lauterbourg 6
Milan 6
Phoenix 6
San Francisco 6
The Dalles 6
Amsterdam 5
Baghdad 5
Bologna 5
Boston 5
Can Tho 5
Casablanca 5
Columbus 5
Da Nang 5
Dhaka 5
Poplar 5
Porto Alegre 5
Ribeirão Preto 5
Salt Lake City 5
Shanghai 5
Totale 5.010
Salva come PNG Salva come JPEG
Nome #
Analysis of potential response predictors to capecitabine/temozolomide in metastatic pancreatic neuroendocrine tumors 223
Exosomes in melanoma: A role in tumor progression, metastasis and impaired immune system activity 160
Gastroenteropancreatic Neuroendocrine Tumors 158
Osteotropism of neuroendocrine tumors: Role of the CXCL12/ CXCR4 pathway in promoting EMT in vitro 154
Bendamustine overcomes resistance to melphalan in myeloma cell lines by inducing cell death through mitotic catastrophe 150
Reviewing the Osteotropism in Neuroendocrine Tumors: The Role of Epithelial-Mesenchymal Transition 150
Everolimus restrains the paracrine pro-osteoclast activity of breast cancer cells 149
Management of Asymptomatic Sporadic Nonfunctioning Pancreatic Neuroendocrine Neoplasms (ASPEN) ≤2 cm: Study Protocol for a Prospective Observational Study 149
Extracellular Vesicles and Epigenetic Modifications Are Hallmarks of Melanoma Progression 148
The Tumor Microenvironment in Neuroendocrine Tumors: Biology and Therapeutic Implications 144
A Delphic consensus assessment: imaging and biomarkers in gastroenteropancreatic neuroendocrine tumor disease management. 143
New insights into the molecular pathogenesis of langerhans cell histiocytosis 142
Parallelism of DOG1 expression with recurrence risk in gastrointestinal stromal tumors bearing KIT or PDGFRA mutations 141
Immune System Evasion as Hallmark of Melanoma Progression: The Role of Dendritic Cells. 140
NETs: Organ-related epigenetic derangements and potential clinical applications 137
The Role of Cytotoxic Chemotherapy in Well-Differentiated Gastroenteropancreatic and Lung Neuroendocrine Tumors. 133
An imbalance between Beclin-1 and p62 expression promotes the proliferation of myeloma cells through autophagy regulation. 123
Erdheim-Chester disease: A systematic review. 123
Analysis of the immune landscape of small bowel neuroendocrine tumors 117
Evaluating Risks and Benefits of Evolving Systemic Treatments of Neuroendocrine Tumors 116
Development of anti-somatostatin receptors CAR T cells for treatment of neuroendocrine tumors 113
Lenalidomide in multiple myeloma: current experimental and clinical data 110
Phase II clinical trial of pasireotide long-acting repeatable in patients with metastatic neuroendocrine tumors 110
The management of refractory carcinoid syndrome: challenges and opportunities ahead 110
Sirtuins and Cancer: Role in the Epithelial-Mesenchymal Transition 108
The expanding role of somatostatin analogs in gastroenteropancreatic and lung neuroendocrine tumors 107
Cerebellar ataxia and exercise intolerance in Erdheim-Chester disease 107
A phase II study of axitinib in advanced neuroendocrine tumors 104
Local treatment for focal progression in metastatic neuroendocrine tumors 102
SNPs in predicting clinical efficacy and toxicity of chemotherapy: Walking through the quicksand 100
Will clinical heterogeneity of neuroendocrine tumors impact their management in the future? Lessons from recent trials 97
Analysis of Postoperative Recurrence in Stage I-III Midgut Neuroendocrine Tumors 97
Radionuclide Therapy for Neuroendocrine Tumors 95
Modified staging classification for pancreatic neuroendocrine tumors on the basis of the American Joint Committee on Cancer and European Neuroendocrine Tumor Society Systems 94
DAXX mutations as potential genomic markers of malignant evolution in small nonfunctioning pancreatic neuroendocrine tumors 94
Effect of vitaxin on hyperactive osteoclastogenesis in multiple myeloma: a preclinical study 93
Role of Bone Targeting Agents in the Prevention of Bone Metastases from Breast Cancer 92
Cell fusion in myeloma marrow microenvironment: role in tumor progression 91
Bone Metastases in Neuroendocrine Tumors: Molecular Pathogenesis and Implications in Clinical Practice 90
Treatment strategies for metastatic neuroendocrine tumors of the gastrointestinal tract. 87
Circulating tumour cells and their association with bone metastases in patients with neuroendocrine tumours 87
Local treatment for focal progression in metastatic neuroendocrine tumors 87
An update on gastroenteropancreatic neuroendocrine tumors 83
Adoptive T-cell immunotherapy in digestive tract malignancies: Current challenges and future perspectives 82
Novel Lenalidomide-based combinations for treatment of multiple myeloma 81
1101MO Development of CAR T-cells for future treatment of NETs 80
Therapy for locoregional disease: pancreas 79
In search of a bone metastasis (BM) gene signature in circulating tumour cells (CTCs) from stage IV breast cancer (BC) patients 76
An update on Merkel cell carcinoma 75
Higher frequency of isolated PMS2 loss in colorectal tumors in Colombian population: preliminary results 73
Non-Melanoma Skin Cancers: Biological and Clinical Features 73
Angiogenesis in NENs, with a focus on gastroenteropancreatic NENs: from biology to current and future therapeutic implications 72
Management of NETs in the Precision Medicine Era 72
The psychological impact of COVID-19 pandemic on patients with neuroendocrine tumors: Between resilience and vulnerability 72
Association of Upfront Peptide Receptor Radionuclide Therapy With Progression-Free Survival Among Patients With Enteropancreatic Neuroendocrine Tumors 72
The current status of somatostatin analogs in the treatment of neuroendocrine tumors and future perspectives 71
A Phase II Study of Ibrutinib in Advanced Neuroendocrine Neoplasms 71
Assessment of bone turnover markers and DXA parameters to predict bone metastasis progression during zoledronate treatment: a single-center experience 69
Efficacy and Toxicity Analysis of mFOLFIRINOX in High-Grade Gastroenteropancreatic Neuroendocrine Neoplasms 69
Advanced small-bowel well-differentiated neuroendocrine tumours: An international survey of practice on 3rd-line treatment 68
Sensitivity and Specificity of the NETest: A Validation Study 67
Emerging Treatment Options for Gastroenteropancreatic Neuroendocrine Tumors 66
Lanreotide dopo octreotide LAR nel pNET in progressione: descrizione di un caso 65
Adamantinoma-like Ewing sarcoma of the salivary glands: a case report and systematic literature review 62
Randomised phase II trial of CAPTEM or FOLFIRI as SEcond-line therapy in NEuroendocrine CArcinomas and exploratory analysis of predictive role of PET/CT imaging and biological markers (SENECA trial): A study protocol 62
Neuroendocrine tumors 61
Reversal of MYB-dependent suppression of MAFB expression overrides leukaemia phenotype in MLL-rearranged AML 59
Antiproliferative Systemic Therapies for Metastatic Small Bowel Neuroendocrine Tumours 57
EPB41L5 is Associated with the Metastatic Potential of Low-grade Pancreatic Neuroendocrine Tumors 54
Somatostatin Analogs for Pancreatic Neuroendocrine Tumors: Any Benefit When KI-67 is ≥10%? 54
Sequencing Treatments in Patients with Advanced Well-Differentiated Pancreatic Neuroendocrine Tumor (pNET): Results from a Large Multicenter Italian Cohort 53
An Immunohistochemical Score as Predictor of the Bone Metastasis Risk in Patients with NETs 53
Novel immunotherapy strategies for treatment of neuroendocrine neoplasms 51
Extrapulmonary Neuroendocrine Carcinomas: Current Management and Future Perspectives 51
Epidemiology of gastroenteropancreatic neuroendocrine neoplasms: a review and protocol presentation for bridging tumor registry data with the Italian association for neuroendocrine tumors (Itanet) national database 45
Impact of the SARS-CoV2 pandemic dissemination on the management of neuroendocrine neoplasia in Italy: a report from the Italian Association for Neuroendocrine Tumors (Itanet) 40
Is NETTER-2 a practice-changing trial? 32
A challenge in emergency department: a case report of oxaliplatin-induced Kounis syndrome 31
Epidemiology and geographic clustering of Erdheim-Chester disease in Italy and France 25
Management of asymptomatic sporadic non-functioning pancreatic neuroendocrine neoplasms no larger than 2 cm: interim analysis of prospective ASPEN trial 24
Radioligand therapy in the therapeutic strategy for patients with gastro-entero-pancreatic neuroendocrine tumors: a consensus statement from the Italian Association for Neuroendocrine Tumors (Itanet), Italian Association of Nuclear Medicine (AIMN), Italian Society of Endocrinology (SIE), Italian Association of Medical Oncology (AIOM) 23
In Defense of Neuroendocrine Tumor Trials 21
The impact of COVID-19 on the management of neuroendocrine tumors (NETS): An international NET CONNECT survey of NET patients and healthcare professionals treating net patients 21
Mixed neuroendocrine non-neuroendocrine tumors: The quest for evidence 20
COVID-19 in patients with neuroendocrine neoplasms: 2-year results of the INTENSIVE study 17
A randomized phase II trial of Captem or Folfiri as second-line therapy in neuroendocrine carcinomas 16
Pancreatic neuroendocrine neoplasms (pNENs): Genetic and environmental biomarkers for risk of occurrence and prognosis 16
Enhancing patient-centered care with AI: a study of responses to neuroendocrine neoplasms queries 15
The future of cellular therapy for the treatment of renal cell carcinoma 14
The Role of Radioligand Therapy in Gastroenteropancreatic Neuroendocrine Tumors: An Italian Expert Opinion 3
White paper on best practices for translational research in neuroendocrine neoplasms 3
Diagnosis and treatment of paragangliomas and pheochromocytomas: a survey from the Italian Association for Neuroendocrine Tumors 3
Peptide receptor radionuclide therapy in G3 gastroenteropancreatic neuroendocrine tumors: a missed opportunity for European patients? 2
Totale 7.599
Salva come PNG Salva come JPEG
Categoria #
all - tutte 36.049
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 36.049
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021470 0 0 0 0 0 87 68 90 33 95 43 54
2021/2022444 42 19 3 10 17 50 14 18 38 37 71 125
2022/2023636 91 111 47 31 37 92 19 87 82 2 17 20
2023/2024313 19 55 14 38 35 63 18 11 6 13 4 37
2024/20251.610 49 27 128 83 57 129 162 129 96 164 207 379
2025/20262.034 557 200 255 472 409 141 0 0 0 0 0 0
Totale 7.599